A Brighter Future — ABF Wellness ShopABF Wellness ShopWellness Shop
Research LibraryPeptide Research

CJC-1295 + Ipamorelin

Investigational Combination

An investigational growth-hormone secretagogue combination; no established human trials support the combination for wellness use.

Insufficient human evidenceLast reviewed October 27, 2026

CJC-1295 and ipamorelin are investigational peptides that influence growth hormone signaling through different mechanisms. CJC-1295 is an analog of growth hormone-releasing hormone, while ipamorelin acts on the ghrelin or growth hormone secretagogue receptor. The combination is promoted in some wellness settings on the theory that stimulating complementary hormonal pathways may enhance growth hormone release. This proposed interaction is not proof of clinical benefit.

Medical information disclaimer

This page is educational only and is not medical advice. It does not describe an approved treatment for every individual and does not guarantee that any product is available for purchase. Investigational compounds are not offered for sale or treatment booking through this storefront. FDA approval applies to specific drug products and indications, not automatically to every formulation containing the same ingredient.

References & Further Reading

  • Controlled CJC-1295 human study — PubMed / National Library of Medicinesource
  • FDA peptide safety assessment — U.S. Food and Drug Administrationsource
  • Published review of injectable peptides — PubMed / National Library of Medicine

This entry was last reviewed on October 27, 2026 and requires clinical review before publication. ABF's medical and legal advisers may revise research findings and regulatory information as evidence changes.

Related Research

Sermorelin

Clinical/Regulatory Review Required

BPC-157

Investigational Peptide

TB-500

Investigational Peptide